Less than a year into the job, Everett Cunningham steps down as Quanterix CEO

colorful brain art model
Jim Gute, who joined Quanterix as chief commercial officer in August, has been named interim president and CEO. (iStock / Getty Images Plus)

Quanterix is on the lookout for a new chief executive once again as Everett Cunningham, who only started the top job back in January, hits the exit.

The company, which is working on ultrasensitive biomarker detection across a range of diseases, named Cunningham president and CEO effective Jan. 19. He came off an 18-month stint at gene-sequencing giant Illumina as its chief commercial officer, having previously held positions at Exact Sciences, Quest Diagnostics, GE Healthcare and Pfizer.

But just 10 months later, he’s out after “accepting another opportunity,” according to a statement. Jim Gute, its new chief commercial officer who was only hired back in August, has become interim president and CEO while Quanterix looks for a permanent leader.

The medtech’s board has “engaged a nationally recognized executive search firm to assist with this process and will consider both internal and external candidates,” it added in the release.

Quanterix is working to improve the detection of Alzheimer’s disease while also seeking to broaden its work in other diseases.

At the end of last year, Quanterix presented new clinical data from its Simoa assay, which it described as the largest population-based assessment of Alzheimer’s disease neuropathological changes to date.

Published in the journal Nature, the research showed that the company’s ultrasensitive test for the phosphorylated tau-217 biomarker can help estimate the prevalence of Alzheimer’s-related neuropathological changes among older individuals. That figure rises sharply from about 10% among people ages 58 to 69 to nearly 65% among those over 90.

The results also suggest that Quanterix's blood test could help identify people with Alzheimer’s-related changes before symptoms appear, potentially allowing them to seek early treatment or enroll in a clinical trial, the company said.

The company and its leadership have, however, been under pressure. In a note to clients published in January when Cunningham was first announced as CEO, Leerink analysts said they “remain cautious” on the company under Cunningham, noting that “transformation and return to growth for the core business will take time to realize.”

The research firm said the “transformation at [Quanterix] remains a significant lift for new leadership.” Leerink also saw the medtech as having “lost its lead in the Alzheimer's [diagnostics] market, with Fujirebio's assay already FDA-approved and C2N's PrecivityAD submitted for approval.”

Fujirebio Diagnostics nabbed an FDA first in May 2025 when the U.S. regulator cleared Lumipulse, the first blood-based in vitro diagnostic device to aid in diagnosing Alzheimer’s disease.